Project Grant K99AI199380
- The National Institute of Allergy and Infectious Diseases awarded Yale University $100,228 on October 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of hookworm glycoproteins in parasite biology and disease pathogenesis. The research characterizes glycosylated antigens in human hookworm species and their roles in immunopathogenesis. The project will identify glycoproteins present throughout hookworm development in two species of human...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center $451,000 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project period (August 1, 2025 – July 31, 2027). This Project Grant supports basic biomedical research investigating how prenatal exposure to maternal helminth (parasitic worm) infections alters immune programming in offspring, with potential...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research to develop tools for marginal zone-specific gene expression manipulation in B cells. The project investigates how mature B cell subsets—follicular, marginal zone, and B-1 cells—contribute to protective immune responses in infection and pathogenic responses...
- The National Institute of Allergy and Infectious Diseases awarded $456,500 to The University of Texas Southwestern Medical Center on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a reproducible sequential infection model that matures laboratory mouse immune responses. The research will define a minimal set of sequential viral and parasitic infections that laboratory mice can be exposed to early in life to recapitulate aspects of wild mice...
- The National Institute of Allergy and Infectious Diseases awarded George Washington University $444,125 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on anthelmintic resistance mechanisms in the hookworm Ancylostoma caninum. The research addresses cross-class selection for anthelmintic resistance, examining how naturally resistant hookworm isolates develop multi-drug resistance across three major anthelmintic classes:...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $191,987 on June 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a postdoctoral research training program in infectious diseases. The UT Southwestern Infectious Diseases Research Training Program supports two postdoctoral physician-scientist trainees annually for two-year training periods. The program recruits physician-scientists...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded $300,000 to the University of Texas Southwestern Medical Center on September 10, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds development of immune checkpoint-engineered oligodendrocytes as a cell-based therapeutic approach for multiple sclerosis. The research builds on prior work demonstrating that immune...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $152,600 on October 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the molecular and cellular mechanisms by which B-alanyl tryptamine (BATT), a recently discovered schistosome pheromone, triggers female sexual maturation in schistosomes. The recipient will conduct research using transcriptomics, proteomics, and functional assays...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $415,000 on May 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support mechanistic research into a novel cell cycle regulator complex for cancer therapy. The research defines mechanisms by which a zinc finger transcription factor complex composed of ZFP574 and THAP12 supports immune development and function, with evaluation of therapeutic...
- The National Institute of Allergy and Infectious Diseases awarded Texas Biomedical Research Institute $927,025 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate IL-21-IGFC therapy for enhancing pulmonary immune reconstitution and limiting viral persistence in co-infected macaques. The research addresses incomplete immune reconstitution in individuals co-infected with HIV and tuberculosis despite antiretroviral therapy, using an established...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center $192,369 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define CD4+ T-cell populations driving protection and susceptibility in hookworm reinfection. The research will characterize immune mechanisms that prevent parasite clearance in chronic helminth infections, with direct applications to prevention, diagnosis, and treatment of parasitic disease in U.S. patients. Work combines mechanistic studies in a rodent hookworm model using immune-cell depletion, adoptive transfer, vaccination, and tissue analysis to identify cellular pathways necessary for acquired protection, paired with complementary studies examining deidentified, cryopreserved blood cells collected from adults with hookworm infection before and after treatment. The research team will employ spectral flow cytometry, activation-induced marker assays, paired single-cell RNA and T-cell receptor sequencing, and functional studies to determine whether infection-associated immune changes reverse after parasite clearance. The project runs through August 31, 2028, with place of performance in Dallas, Texas. This K99/R00 career development award supports a transition from postdoctoral research training to independent investigator status.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $192.4k | 9/1/26 |